Personalised Medicine & Disease Modification in OA

In this article we discuss the challenges in demonstrating disease modification in OA, illustrate this with examples of recently published clinical trials, and describe the current status of APPA, a novel, patented potential Disease Modifying Osteoarthritic Drug (DMOAD).

Read More

How close are disease‐modifying drugs for OA?

Progress in the development of disease‐modifying drugs for osteoarthritis has been hampered by a lack of understanding of the pathogenesis of the disease and how it differs from rheumatoid arthritis. However, more recent research in this field has identified several promising therapeutic targets. The symptoms of osteoarthritis, the most common joint disorder, typically emerge at […]

Read More

Phase II osteoarthritis clinical trial underway

The APPA Phase II human trial is being conducted by AKLRD's partner Nordic Bioscience Clinical Development (NBCD), following the successful completion of Phase I.

Read More

Partnership with a top 5 animal health company

AKL Research and Development has partnered with a world-leading animal health company to test APPA in dogs AKLRD has signed an agreement with one of the world’s top five animal health companies to fund the development of its next-stage clinical trial in canine OA. Osteoarthritis is the most common form of arthritis in dogs, affecting […]

Read More

Abstract published at EULAR 2020

An abstract on a series of uncontrolled patient cases evaluating the efficacy and safety of APPA in patients with osteoarthritis has been published at EULAR 2020 Treatment with APPA was reported as effective by 82.6% of patients, all of whom had failed to have an adequate response with standard prescribed medications. Full abstract is available […]

Read More

New research published on APPA’s mode of action

APPA modulates pathological aspects of human neutrophil function, without suppressing antimicrobial ability, and inhibits TNFα expression and signalling A greater understanding of neutrophil biology has led to an appreciation that these cells play a significant role in many systemic inflammatory conditions but targeting neutrophils therapeutically has proven challenging, as host defences must not be compromised. […]

Read More